Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation
- PMID:25453482
- DOI: 10.1016/j.euroneuro.2014.09.016
Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation
Abstract
The brain׳s complexity derives not only from the way the intricate network of neurons is wired, but also by protein complexes that recognize and decode chemical information. G protein-coupled receptors (GPCRs) represent the most abundant family of proteins mediating neurotransmission in the brain, and their ability to form homo- and heteromers which amplifies the scope for synaptic communication and fine-tuning. Dopamine receptors are important drug targets and members of both the D1/D5 and D2/D3/D4 receptor families form homo- and heteromers. The present article focuses on D3 receptor homo- and heteromers, in particular, those formed in association with their D2 counterparts. We highlight the binding profiles and mechanisms of interaction with D3-D3 homomers and D3-D2 heteromers of: first, the PET ligand and potent agonist [(11)C]-(+)-PHNO; second, the novel, bitopic/allosteric dopamine D3 receptor antagonist, SB269,652; and third, diverse partial agonists like antipsychotic and aripiprazole. Molecular mechanisms of interplay between the two protomers of heteromeric D3-D2 complexes are likewise discussed: for example, "transactivation", whereby recruitment of one member of a heteromer harnesses signalling pathways is normally coupled to the other protomer. Finally, D1 receptor heteromers are also taken into consideration in deciphering the nature of interfaces required to stabilize dimeric assemblies and permit their interaction with G proteins. Improved understanding of D3 as well as D2 and D1 receptor complexes should yield important insights into their physiological roles and pathological significance, and permit the development of novel drug classes with potentially distinctive functional profiles and improved therapeutic windows.
Keywords: Antiparkinson; Antipsychotic; Aripiprazole; G-protein; Heteromerization; PHNO.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.
Similar articles
- Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?Carli M, Kolachalam S, Aringhieri S, Rossi M, Giovannini L, Maggio R, Scarselli M.Carli M, et al.Curr Neuropharmacol. 2018 Jan 30;16(2):222-230. doi: 10.2174/1570159X15666170518151127.Curr Neuropharmacol. 2018.PMID:28521704Free PMC article.Review.
- Targeting the dopamine D3 receptor: an overview of drug design strategies.Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V.Cortés A, et al.Expert Opin Drug Discov. 2016 Jul;11(7):641-64. doi: 10.1080/17460441.2016.1185413. Epub 2016 May 30.Expert Opin Drug Discov. 2016.PMID:27135354Review.
- Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.Maggio R, Aloisi G, Silvano E, Rossi M, Millan MJ.Maggio R, et al.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S2-7. doi: 10.1016/S1353-8020(09)70826-0.Parkinsonism Relat Disord. 2009.PMID:20123551Review.
- Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors.Fasciani I, Pietrantoni I, Rossi M, Mannoury la Cour C, Aloisi G, Marampon F, Scarselli M, Millan MJ, Maggio R.Fasciani I, et al.Eur J Pharmacol. 2018 Jan 15;819:181-189. doi: 10.1016/j.ejphar.2017.12.002. Epub 2017 Dec 6.Eur J Pharmacol. 2018.PMID:29223348
- Evidence for the heterotetrameric structure of the adenosine A2A-dopamine D2 receptor complex.Casadó-Anguera V, Bonaventura J, Moreno E, Navarro G, Cortés A, Ferré S, Casadó V.Casadó-Anguera V, et al.Biochem Soc Trans. 2016 Apr 15;44(2):595-600. doi: 10.1042/BST20150276.Biochem Soc Trans. 2016.PMID:27068975Review.
Cited by
- Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brainin vivo.Kiss B, Krámos B, Laszlovszky I.Kiss B, et al.Front Psychiatry. 2022 Mar 24;13:785592. doi: 10.3389/fpsyt.2022.785592. eCollection 2022.Front Psychiatry. 2022.PMID:35401257Free PMC article.Review.
- DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis.Barroso-Chinea P, Luis-Ravelo D, Fumagallo-Reading F, Castro-Hernandez J, Salas-Hernandez J, Rodriguez-Nuñez J, Febles-Casquero A, Cruz-Muros I, Afonso-Oramas D, Abreu-Gonzalez P, Moratalla R, Millan MJ, Gonzalez-Hernandez T.Barroso-Chinea P, et al.Autophagy. 2020 Jul;16(7):1279-1295. doi: 10.1080/15548627.2019.1668606. Epub 2019 Oct 2.Autophagy. 2020.PMID:31538542Free PMC article.
- Review on allosteric modulators of dopamine receptors so far.Girmaw F.Girmaw F.Health Sci Rep. 2024 Mar 18;7(3):e1984. doi: 10.1002/hsr2.1984. eCollection 2024 Mar.Health Sci Rep. 2024.PMID:38505681Free PMC article.
- A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization.Marsango S, Caltabiano G, Jiménez-Rosés M, Millan MJ, Pediani JD, Ward RJ, Milligan G.Marsango S, et al.Sci Rep. 2017 May 18;7(1):2134. doi: 10.1038/s41598-017-02249-3.Sci Rep. 2017.PMID:28522847Free PMC article.
- Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection.Bono F, Mutti V, Fiorentini C, Missale C.Bono F, et al.Biomolecules. 2020 Jul 9;10(7):1016. doi: 10.3390/biom10071016.Biomolecules. 2020.PMID:32659920Free PMC article.Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources